Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   94663 News 


«12...5556575859606162636465...10641065»
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Facial cutaneous Rosai-Dorfman disease: a (Pubmed Central) -  Mar 31, 2024   
    These findings suggest that simple assessment of adverse-effect bother while receiving treatment is an efficient way to indicate treatment tolerability and ETD risk. Although cutaneous Rosai-Dorfman disease is considered benign and well medical responded disease, patients with atypical presentation and rapid growing lesion may necessitate aggressive multimodal treatment.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Multifunctional hyaluronic acid/gelatin methacryloyl core-shell microneedle for comprehensively treating oral mucosal ulcers. (Pubmed Central) -  Mar 30, 2024   
    The MNs contained a methacrylate gelatin shell layer of basic fibroblast growth factor (bFGF), a hyaluronic acid (HA) core loaded with dexamethasone (DXMS), and zeolite imidazoline framework-8 (ZIF-8) encapsulated in the HA-based backplane...Moreover, the rapid release of HA and, subsequently, DXMS inhibited inflammation, and the remaining MN backing after the tip dissolved behaved as a dressing, releasing ZIF-8 for its antimicrobial effects. This novel, multifunctional, transmucosal core-shell MN patch exhibited excellent anti-inflammatory, antimicrobial, and pro-healing effects in vivo and in vitro, suggesting that it can promote oral ulcer healing.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Wunderlich syndrome as a rare complication of polyarteritis nodosa: a case report. (Pubmed Central) -  Mar 29, 2024   
    After the exclusion of infectious or neoplastic foci, the patient was diagnosed with PAN and started intravenous methylprednisolone pulses with a good response. Since WS is a rare initial clinical manifestation of PAN, an early diagnosis and aggressive treatment will significantly improve clinical outcomes.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Journal:  ?2,6-sialic Acid on the Platelet Membrane Surface is a Novel Biomarker and Therapeutic Target in Children with Primary Immune Thrombocytopenia. (Pubmed Central) -  Mar 29, 2024   
    All children were treated with dexamethasone (DXMS) shock therapy; Another 20 healthy children who underwent routine physical examination at the same time were selected and included in the control group...The sialylation of platelet membrane glycoprotein may be involved in the occurrence and development of the disease. It is of great practical significance to diagnose and evaluate the therapeutic effect of the disease by detecting the sialylation of platelet membrane glycoprotein.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  External Validation of Prognostic Models in Critical Care: A Cautionary Tale From COVID-19 Pneumonitis. (Pubmed Central) -  Mar 29, 2024   
    Our findings, albeit from a single center, suggest that the published performance of COVID-19 prediction models may not be replicated when translated to other institutions. In light of this, we would encourage bedside intensivists to reflect on the role of clinical prediction models in their own clinical decision-making.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Glucocorticoid-mediated immunosuppression prolongs SARS-CoV-2 replication in the lower airways of rhesus macaques (Exhibit Hall F1; Poster Board Number: B222) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2024;    
    Rhesus macaques were pre-treated with intravenous methylprednisolone or saline daily for 5 days and then infected with SARS-CoV-2 delta (B.1.617.2) and animals receiving glucocorticoids were maintained on oral prednisolone...SARS-CoV-2 specific CD8 T cell responses in the airways were also reduced with GC treatment, as were B cells and TFH responses in secondary lymphoid organs. Overall, glucocorticoid treatment during SARS-CoV-2 infection reduced lung inflammation, impaired host immune responses, and delayed viral clearance from the lower respiratory tract.
  • ||||||||||  Aerospan (flunisolide HFA) / Viatris, AbbVie
    Enhanced host protection and survival to Listeria monocytogenes infection after small molecule innate training (Exhibit Hall F1; Poster Board Number: B764) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1690;    
    Here, we aim to show the protective potential of flunisolide (FN) using live infection model...Furthermore, FN mice showed improved survival up to d7. We showed FN can induce innate training, altering BM landscape at homeostasis and after infection, with improved response to L. monocytogenes.
  • ||||||||||  cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    IGA VASCULITIS PRESENTING AS GUILLAIN-BARR (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2592;    
    Figure 1. Confluent purple macules palpable on the external malleolus of the right leg compatible with palpable purpura
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    CEREBRAL SINUS VEIN THROMBOSIS IN VEXAS SYNDROME (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2570;    
    He was treated with prednisone, and after diagnosis, tocilizumab was introduced with resolution of all inflammatory symptoms and markers, while prednisone was tapered to 7.5 mg/day...The patient was treated with IV methylprednisolone, parenteral anticoagulation (AC), endovascular thrombectomy, and intracranial pressure lowering agents, but unfortunately died 3 weeks after presentation...The event occurred during apparently quiescent inflammatory status, under treatment with tocilizumab which may mask persistent inflammation. As our understanding is evolving, specific immunomodulators and AC may be recommended in the future.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    SINGLE NUCLEI TRANSCRIPTOMIC STUDY OF INTRA-ARTICULAR METHYLPREDNISOLONE EFFECTS ON INFLAMMATORY ARTHRITIS SYNOVIUM (A8.1) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2041;    
    This study has the advantage of characterising paired synovium tissues before and after treatment, at single cell resolution in an unbiased approach, allowing characterisation of gene pathway analysis in cells such as adipocytes. These novel insights will advance our understanding of the cells including adipocytes involved in the pathogenesis and resolution of inflammatory arthritis.
  • ||||||||||  prednisolone / Generic mfg.
    IMPROVING PATIENT SAFETY VIA THE DEVELOPMENT OF A PHARMACIST-LED GLUCOCORTICOID COUNSELLING SERVICE (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2025;    
    Additionally, it enabled the identification and rectification of gaps in monitoring for adverse events and increased patient safety. Our service identified that providing patients with written information alone is inadequate and that counselling outside of the clinical consultation is effective and well-received by patients.
  • ||||||||||  Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
    ULTRASOUND REMISSION RATES AFTER 1 YEAR ARE HIGH IN EARLY RA PATIENTS ON INDUCTION TREATMENT: RESULTS FROM THE RANDOMIZED NORD-STAR TRIAL (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_756;    
    About 1 in 6 patients lost response with repeat cycles and this was associated with a 2NDNR phenomenon. Background: The randomized controlled NORD-STAR trial demonstrated remission rates of 40-60% in patients with early rheumatoid arthritis (RA) at 24 and 48 weeks according to the Clinical Disease Activity Index (CDAI) when treated early with methotrexate in combination with prednisolone (active conventional therapy (ACT)), certolizumab pegol (CZP), abatacept (ABA) or tocilizumab (TCZ) (1, 2)...Treatment-na
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Trial primary completion date:  Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (clinicaltrials.gov) -  Mar 29, 2024   
    P3,  N=150, Recruiting, 
    Background: The randomized controlled NORD-STAR trial demonstrated remission rates of 40-60% in patients with early rheumatoid arthritis (RA) at 24 and 48 weeks according to the Clinical Disease Activity Index (CDAI) when treated early with methotrexate in combination with prednisolone (active conventional therapy (ACT)), certolizumab pegol (CZP), abatacept (ABA) or tocilizumab (TCZ) (1, 2)...Treatment-na Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Enrollment closed, Trial primary completion date, MRI:  ETHA: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (clinicaltrials.gov) -  Mar 29, 2024   
    P3,  N=31, Active, not recruiting, 
    Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Aug 2023
  • ||||||||||  belrestotug (EOS-448) / iTeos, GSK
    Enrollment change, Trial completion date, Trial termination, Combination therapy:  Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) -  Mar 28, 2024   
    P1/2,  N=16, Terminated, 
    N=162 --> 16 | Trial completion date: Dec 2025 --> Nov 2023 | Recruiting --> Terminated; Company operational decision. Decision to stop study is not due to safety or efficacy concerns
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Intralesional Steroid Injection Versus Voice Therapy in Management of Vocal Nodules (clinicaltrials.gov) -  Mar 28, 2024   
    P4,  N=40, Recruiting, 
    Decision to stop study is not due to safety or efficacy concerns Unknown status --> Recruiting | Trial completion date: Feb 2022 --> Sep 2025 | Trial primary completion date: May 2021 --> May 2025